These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 31443225)

  • 41. Uric acid and incident chronic kidney disease in a large health check-up population in Taiwan.
    Wang S; Shu Z; Tao Q; Yu C; Zhan S; Li L
    Nephrology (Carlton); 2011 Nov; 16(8):767-76. PubMed ID: 21854506
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oral uricase eliminates blood uric acid in the hyperuricemic pig model.
    Szczurek P; Mosiichuk N; Woliński J; Yatsenko T; Grujic D; Lozinska L; Pieszka M; Święch E; Pierzynowski SG; Goncharova K
    PLoS One; 2017; 12(6):e0179195. PubMed ID: 28594873
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of allopurinol on the glomerular filtration rate of children with chronic kidney disease.
    Ghane Sharbaf F; Assadi F
    Pediatr Nephrol; 2018 Aug; 33(8):1405-1409. PubMed ID: 29549464
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of ferulic acid consumption in ameliorating the cadmium-induced liver and renal oxidative damage in rats.
    Sanjeev S; Bidanchi RM; Murthy MK; Gurusubramanian G; Roy VK
    Environ Sci Pollut Res Int; 2019 Jul; 26(20):20631-20653. PubMed ID: 31104231
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oxidative stress, circulating antioxidants, and dietary preferences in songbirds.
    Alan RR; McWilliams SR
    Comp Biochem Physiol B Biochem Mol Biol; 2013 Mar; 164(3):185-93. PubMed ID: 23270695
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Is increased uric acid a risk factor or a defensive response? The Campania Salute Network.
    Mancusi C; Izzo R; Ferrara LA; Rozza F; Losi MA; Canciello G; Pepe M; de Luca N; Trimarco B; de Simone G
    Nutr Metab Cardiovasc Dis; 2018 Aug; 28(8):839-846. PubMed ID: 29898822
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of topiroxostat in hyperuricemic patients with chronic kidney disease.
    Horino T; Hatakeyama Y; Ichii O; Matsumoto T; Shimamura Y; Inoue K; Terada Y; Okuhara Y
    Clin Exp Nephrol; 2018 Apr; 22(2):337-345. PubMed ID: 28752287
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The relationships among hyperuricemia, body mass index and impaired renal function in type 2 diabetic patients.
    Li Y; Fan X; Li C; Zhi X; Peng L; Han H; Sun B
    Endocr J; 2018 Mar; 65(3):281-290. PubMed ID: 29237999
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The paradoxical relationship between serum uric acid and cardiovascular disease.
    Lippi G; Montagnana M; Franchini M; Favaloro EJ; Targher G
    Clin Chim Acta; 2008 Jun; 392(1-2):1-7. PubMed ID: 18348869
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
.
    Kwak CH; Sohn M; Han N; Cho YS; Kim YS; Oh JM
    Int J Clin Pharmacol Ther; 2018 Jul; 56(7):321-327. PubMed ID: 29750634
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Uric acid in CKD: has the jury come to the verdict?
    Bonino B; Leoncini G; Russo E; Pontremoli R; Viazzi F
    J Nephrol; 2020 Aug; 33(4):715-724. PubMed ID: 31933161
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Uric acid, CKD, and cardiovascular disease: confounders, culprits, and circles.
    Tangri N; Weiner DE
    Am J Kidney Dis; 2010 Aug; 56(2):247-50. PubMed ID: 20659624
    [No Abstract]   [Full Text] [Related]  

  • 53. Adenine-induced chronic kidney and cardiovascular damage in rats.
    Diwan V; Mistry A; Gobe G; Brown L
    J Pharmacol Toxicol Methods; 2013; 68(2):197-207. PubMed ID: 23732959
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Allopurinol Against Progression of Chronic Kidney Disease.
    Golmohammadi S; Almasi A; Manouchehri M; Omrani HR; Zandkarimi MR
    Iran J Kidney Dis; 2017 Jul; 11(4):286-293. PubMed ID: 28794291
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects on serum uric acid by difference of the renal protective effects with atorvastatin and rosuvastatin in chronic kidney disease patients.
    Kose E; An T; Kikkawa A; Matsumoto Y; Hayashi H
    Biol Pharm Bull; 2014; 37(2):226-31. PubMed ID: 24492719
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hyperuricemia as an independent risk factor of chronic kidney disease in middle-aged and elderly population.
    Chang HY; Tung CW; Lee PH; Lei CC; Hsu YC; Chang HH; Yang HF; Lu LC; Jong MC; Chen CY; Fang KY; Chao YS; Shih YH; Lin CL
    Am J Med Sci; 2010 Jun; 339(6):509-15. PubMed ID: 20421785
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of uric acid dysregulation on the kidney.
    Dissanayake LV; Spires DR; Palygin O; Staruschenko A
    Am J Physiol Renal Physiol; 2020 May; 318(5):F1252-F1257. PubMed ID: 32223309
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum uric acid and mortality in chronic kidney disease: A systematic review and meta-analysis.
    Xia X; Luo Q; Li B; Lin Z; Yu X; Huang F
    Metabolism; 2016 Sep; 65(9):1326-41. PubMed ID: 27506740
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Uric acid and inflammation in kidney disease.
    Jung SW; Kim SM; Kim YG; Lee SH; Moon JY
    Am J Physiol Renal Physiol; 2020 Jun; 318(6):F1327-F1340. PubMed ID: 32223310
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association.
    Mallat SG; Al Kattar S; Tanios BY; Jurjus A
    Curr Hypertens Rep; 2016 Oct; 18(10):74. PubMed ID: 27696189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.